0001415889-24-002613.txt : 20240205 0001415889-24-002613.hdr.sgml : 20240205 20240205173910 ACCESSION NUMBER: 0001415889-24-002613 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240201 FILED AS OF DATE: 20240205 DATE AS OF CHANGE: 20240205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Eydelman Mikhail CENTRAL INDEX KEY: 0001918033 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39323 FILM NUMBER: 24597070 MAIL ADDRESS: STREET 1: C/O VAXCYTE, INC. STREET 2: 825 INDUSTRIAL ROAD, SUITE 300 CITY: SAN CARLOS STATE: CA ZIP: 94070 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vaxcyte, Inc. CENTRAL INDEX KEY: 0001649094 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 464233385 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 825 INDUSTRIAL ROAD, STE. 300 CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 650-837-0111 MAIL ADDRESS: STREET 1: 825 INDUSTRIAL ROAD, STE. 300 CITY: SAN CARLOS STATE: CA ZIP: 94070 FORMER COMPANY: FORMER CONFORMED NAME: SutroVax, Inc. DATE OF NAME CHANGE: 20150724 4 1 form4-02052024_100258.xml X0508 4 2024-02-01 0001649094 Vaxcyte, Inc. PCVX 0001918033 Eydelman Mikhail C/O VAXCYTE, INC. 825 INDUSTRIAL ROAD, SUITE 300 SAN CARLOS CA 94070 false true false false SVP, GEN COUNSEL & CORP SEC 1 Common Stock 2024-02-01 4 M 0 1667 21.41 A 22377 D Common Stock 2024-02-01 4 S 0 212 72.215 D 22165 D Common Stock 2024-02-01 4 S 0 638 73.165 D 21527 D Common Stock 2024-02-01 4 S 0 343 74.11 D 21184 D Common Stock 2024-02-01 4 S 0 474 75.391 D 20710 D Stock Option (Right to Buy) 21.41 2024-02-01 4 M 0 1667 0 D 2032-05-08 Common Stock 1667 191666 D The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 29, 2023. The price reported is a weighted-average price. The shares were sold at prices ranging from $71.69 to $72.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The price reported is a weighted-average price. The shares were sold at prices ranging from $72.695 to $73.67. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The price reported is a weighted-average price. The shares were sold at prices ranging from $73.70 to $74.52. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The price reported is a weighted-average price. The shares were sold at prices ranging from $75.01 to $75.70. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. 1/4 of the shares subject to the option shall vest on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date. Mikhail Eydelman, by /s/ Andrew Guggenhime, Attorney-in-Fact 2024-02-05